The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMDX | +98.35% | -79.7% | -27.28% | -95% |
| S&P | +19.89% | +109.18% | +15.89% | +235% |
Insight Molecular Diagnostics Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
The announcement of a new share issue usually drives a stock's price down, after all.
A bit of profit taking after huge gains yesterday is pressuring the liquid biopsy developer.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.52M | 398.1% |
| Gross Profit | -$0.19M | 18.0% |
| Gross Margin | -36.49% | 185.1% |
| Market Cap | $86.37M | 119.1% |
| Market Cap / Employee | $1.76M | 0.0% |
| Employees | 49 | 6.5% |
| Net Income | -$9.74M | -115.1% |
| EBITDA | -$6.48M | -21.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $24.29M | 162.4% |
| Accounts Receivable | $0.51M | 502.4% |
| Inventory | 0.7 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.83M | -30.5% |
| Short Term Debt | $1.54M | 49.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -101.28% | -56.7% |
| Return On Invested Capital | 67.90% | 135.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.63M | -7.4% |
| Operating Free Cash Flow | -$6.28M | -5.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.68 | 3.28 | -4.35 | 8.45 | 301.35% |
| Price to Sales | 55.13 | 21.99 | 20.46 | 22.72 | -38.79% |
| Price to Tangible Book Value | -1.13 | -0.68 | -1.99 | -19.71 | 3533.20% |
| Enterprise Value to EBITDA | -6.58 | -7.49 | -9.41 | -11.70 | 92.84% |
| Return on Equity | -165.3% | -910.9% | -429.0% | -532.9% | 423.66% |
| Total Debt | $3.99M | $3.66M | $3.48M | $3.37M | -7.99% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
